Liwanli Innovation Co (TPE:3054) EBIT: NT$158.9 Mil (TTM As of Dec. 2025)


TPE:3054 Liwanli Innovation Co Ltd TPE:3054
57 GF Score
Price NT$61.60
GF Value NT$39.71
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Liwanli Innovation Co EBIT?

Liwanli Innovation Co TPE:3054 -6.10% 57 EBIT is NT$158.9 Mil as of Dec. 2025. GuruFocus rates TPE:3054 with a GF Score™ of 57/100 and a GF Value™ of NT$39.71 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Liwanli Innovation Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$105.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$158.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Liwanli Innovation Co's annualized ROC % for the quarter that ended in Dec. 2025 was -30.24%. Liwanli Innovation Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 795.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Liwanli Innovation Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 3.51%.


Liwanli Innovation Co  (TPE:3054) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Liwanli Innovation Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-180.392 * ( 1 - 0.33% )/( (567.344 + 621.629)/ 2 )
=-179.7967064/594.4865
=-30.24 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=921.629 - 27.168 - ( 327.117 - max(0, 32.691 - 407.329+327.117))
=567.344

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1141.666 - 73.356 - ( 446.681 - max(0, 79.441 - 559.815+446.681))
=621.629

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Liwanli Innovation Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=421.2/( ( (12.079 + max(45.863, 0)) + (12.81 + max(35.141, 0)) )/ 2 )
=421.2/( ( 57.942 + 47.951 )/ 2 )
=421.2/52.9465
=795.52 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(16.288 + 58.862 + 3.404) - (27.168 + 0 + 5.523)
=45.863

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.835 + 98.946 + 3.9110000000001) - (73.356 + 0 + 4.195)
=35.141

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Liwanli Innovation Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=158.937/4524.120
=3.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Liwanli Innovation Co EBIT Related Terms


Liwanli Innovation Co EBIT Historical Data

* Premium members only.

The historical data trend for Liwanli Innovation Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liwanli Innovation Co EBIT Chart

Liwanli Innovation Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.75 -119.94 5.30 -30.39 158.94

Liwanli Innovation Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.92 -0.75 0.95 53.43 105.30

TPE:3054 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liwanli Innovation Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Liwanli Innovation Co's EV-to-EBIT falls into.


TPE:3054
57GF Score
Liwanli Innovation Co Ltd TPE:3054
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liwanli Innovation Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$158.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$158.9 Mil mean?
Liwanli Innovation Co (TPE:3054) has a EBIT of NT$158.9 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Liwanli Innovation Co.
Is Liwanli Innovation Co's EBIT too high?
Liwanli Innovation Co's current EBIT is NT$158.9 Mil. Overall, Liwanli Innovation Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's EBIT compare to ZTS?
Liwanli Innovation Co's EBIT of NT$158.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Liwanli Innovation Co. Liwanli Innovation Co's current EBIT is NT$158.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.71, compared to a current price of NT$61.60 — trading 55.1% above its estimated fair value. The current EBIT is NT$158.9 Mil. Liwanli Innovation Co's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current EBIT is NT$158.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?

Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be overvalued. The current stock price of NT$61.60 is trading 55.1% above its estimated GF Value™ of NT$39.71. GuruFocus considers Liwanli Innovation Co to be Significantly Overvalued.

Key valuation signals for TPE:3054:

  • EBIT: NT$158.9 Mil
  • GF Value™: NT$39.71 vs. price of NT$61.60 (55.1% above fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Liwanli Innovation Co Business Description

Address No. 537, Tanmei Street, 9th Floor, Neihu District, Taipei City, TWN, 235
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
57GF Score

Get the complete analysis for TPE:3054

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$61.60
Price
NT$39.71
GF Value